Group items tagged

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that: * Compare different patient care approaches. * Include patient-centric outcome assessments. * Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices. * Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes. * Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma. All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination The Common Funds Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data.

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions.  The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).  

"Solicitation of Proposals to Conduct Research Using Microgravity Simulation Devices" NASA Research Announcement (NRA) Appendix D - NNH16ZTT001N-MS NRA This National Aeronautics and Space Administration Research Announcement: "Solicitation of Proposals to Conduct Research Using Microgravity Simulation Devices" is an Appendix to the NASA Omnibus Research Announcement ROSBio-2016 (NNH16ZTT001N NRA). This Appendix solicits proposals that will use microgravity simulation devices to test specific hypotheses regarding the effects of altered gravity on biological systems, including cells, tissues, microorganisms, plants, and whole organisms. Proposing investigators will have the option of using the Microgravity Simulation Support Laboratory (MSSL) at the Kennedy Space Center, or using microgravity simulation devices at other locations. Proposals must address Space Biology research emphases, visions, and goals identified in the ROSBio-2016 Omnibus NRA or in the Space Biology Science Plan 2016-2025, and/or recommendations from the Decadal Survey.

The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

A major objective of this funding opportunity announcement (FOA) is to invite SBIR applications to foster collaboration between clinical and bioengineering research communities to develop and test safe, accurate, and effective devices for use in neonatal, perinatal, and pediatric care settings. These can be new devices or improvements on existing devices. The studies may range from concept to developmental phases, with a clear commercialization plan to enable healthcare providers to use them in regular clinical care settings in the population, which is the focus of this FOA.

The purpose of this FOA is the rapid and efficient translation of innovative laboratory research findings into therapies, devices or other resources for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological interventions, such as gene therapy, cell-based therapy, pharmacological approaches, and/or medical devices. The ultimate goal of this program is to make technological, biological and pharmacological resources available to clinicians and their patients. Each project should have a well-defined end-point, achievable within a five-year time frame, of developing a device or treatment for a specific ocular disease.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.

The Nano-Biosensing program is part of the Engineering Biology and Health cluster, which includes also 1) Cellular and Biochemical Engineering; 2) Engineering of Biomedical Systems; 3) Biophotonics; and 4) Disability and Rehabilitation Engineering. The Nano-Biosensing program supports fundamental engineering research on devices and methods for measurement and quantification of biological analytes. Proposals that incorporate emerging nanotechnology methods are especially encouraged. Areas of interest include: -Multi-purpose sensor platforms that exceed the performance of current state-of-the-art devices. -Novel transduction principles, mechanisms and sensor designs suitable for measurement in practical matrix and sample-preparation-free approaches. These include error-free detection of pathogens and toxins in food matrices, waterborne pathogens, parasites, toxins, biomarkers in body fluids, and others that improve human condition. -Nano-biosensors that enable measurement of biomolecular interactions in their native states, transmembrane transport, intracellular transport and reactions, and other biological phenomena. -Studies that examine intracellular measurements must include discussion on the significance of the measurement. 

DARPA seeks new methods for analysis and decoding of neural signals in order to understand how neural stimulation could be applied to facilitate recovery of memory encoding following brain injury. Ultimately, it is desired to develop a prototype implantable neural device that enables recovery of memory in a human clinical population. Additionally, the program encompasses the development of quantitative models of complex, hierarchical memories and exploration of neurobiological and behavioral distinctions between memory function using the implantable device versus natural learning and training.

The world needs more effective, functional and affordable technology solutions to clinical medical problems. With the BMEidea competition, the nation's leading competition for biomedical and bioengineering students, we challenge students to pioneer a health-related technology that addresses a real clinical need. Competition entries are judged on: Technical, economic and regulatory feasibility Contribution to human health and quality of life Technological innovation Potential for commercialization Strong BMEidea submissions define a problem and demonstrate the development of a device, product, or technology designed to solve it. BMEidea awards are presented each year at the MD&M East Medical Device Trade Show and Convention. Competition winners will receive cash awards as well as access to resources to be used for further development and commercialization of their products. In addition, the first place institution will get to display the BMEidea trophy in their winning department for the year.

The purpose of this FOA is the rapid and efficient translation of innovative laboratory research findings into therapies, devices or other resources for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians will focus on generating preclinical data that will lead to the development of biological interventions, such as gene therapy, cell-based therapy, pharmacological approaches, and/or medical devices. The ultimate goal of this program is to make technological, biological and pharmacological resources available to clinicians and their patients.

The Michael J. Fox Foundation will award one-to-two-year grants to test non-pharmacological interventions for the treatment of gait and balance disturbances in people with Parkinson's disease (PD). We are particularly interested in proof-of-concept, validation and data-analysis projects. This program seeks proposals for research studying the therapeutic benefit of: Assistive devices (e.g., back or leg braces). Novel technologies (e.g., laser or wearable devices). Rehabilitative therapy programs (e.g., occupational or physical therapy)

The National Science Foundation (NSF), through the Directorate for Engineering, the Directorate of Computer and Information Science and Engineering Division of Computer and Network Systems, and the Directorate for Mathematical and Physical Sciences Division of Materials Research, along with the U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH), have established the NSF/FDA Scholar-in-Residence Program at FDA. This program comprises an interagency partnership for the investigation of scientific and engineering issues concerning emerging trends in medical device technology. This partnership is designed to enable investigators in science, engineering, and computer science to develop research collaborations within the intramural research environment at the FDA. This solicitation features three flexible mechanisms for support of research at the FDA: 1) Principal Investigators at FDA; 2) Postdoctoral Researchers at FDA; and 3) Graduate Students at FDA.

The Nano-Biosensing program is part of the Engineering Biology and Health cluster, which includes also 1) Cellular and Biochemical Engineering; 2) Engineering of Biomedical Systems; 3) Biophotonics; and 4) Disability and Rehabilitation Engineering. The Nano-Biosensing program supports fundamental engineering research on devices and methods for measurement and quantification of biological analytes. Proposals that incorporate emerging nanotechnology methods are especially encouraged. Areas of interest include: Multi-purpose sensor platforms that exceed the performance of current state-of-the-art devices. Novel transduction principles, mechanisms and sensor designs suitable for measurement in practical matrix and sample-preparation-free approaches. These include error-free detection of pathogens and toxins in food matrices, waterborne pathogens, parasites, toxins, biomarkers in body fluids, and others that improve human condition. Nano-biosensors that enable measurement of biomolecular interactions in their native states, transmembrane transport, intracellular transport and reactions, and other biological phenomena. Studies that examine intracellular measurements must include discussion on the significance of the measurement.

JDRF is launching an initiative to accelerate the development of "open-protocol" automated insulin delivery (artificial pancreas) systems. JDRF is soliciting proposals from insulin pump manufacturers and continuous glucose monitor (CGM) manufacturers that will enable seamless, secure connectivity with other devices (e.g., by using Bluetooth technology). JDRF remains committed to supporting the traditional, proprietary commercial development of artificial pancreas systems; in parallel, JDRF will launch efforts in the United States and globally to partner with regulators and legal experts to establish predictable approval pathways for systems that allow for secure, open-protocol-based control through commercially developed devices and software

The FY19 VRP Translational Research Award is intended to support translational research that moves promising discoveries into clinical applications that will advance the prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Successful applications to the FY19 VRP TRA should establish a clear path to transform a discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials. It is expected that an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance. Applicants are strongly encouraged to include at least one collaborator with expertise in the U.S. Food and Drug Administration (FDA) regulatory approval process on the investigative team.

Pandemics have far reaching consequences that range from deaths to shutting down the economy as we have witnessed during the recent COVID19 crisis. Hence there is a need to be better prepared for such pandemics. We need to solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. The social and economic impact for the above areas is huge and some of the work can be transformative and save lives. Areas of interest to us include, but are not limited to: - Mathematical models for spread and the impact of pandemics. - Scalable simulation techniques for pandemics (e.g. with multi agents). - Biomedical/Nano sensor devices for detecting symptoms and agents. - Algorithms for rapid exploration of the drug screening and discovery workflows (e.g. use reinforcement learning) - Advanced computational biology techniques for sequencing, detecting viral evolution (e.g. in COVID-19). - Algorithms and systems for contact tracing (with privacy preserving). - Algorithms and recommendation systems for curating media and news. - Collaboration techniques for more effective health, and efficiency during pandemics. Improved identity and security techniques. - Distributed Ledgers, their applications and their governance for and during pandemics. - Pandemic data science - understanding the patterns and the impact of a pandemic like COVID-10. Creation of curated data sets. We are interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them.

The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of particular interest.

The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of particular interest.